#USA #Breast Cancer #Transpara #ScreenPoint Medical #Nijmegen

ScreenPoint Medical's Transpara® AI in a Groundbreaking Breast Cancer Trial

In a significant advancement in breast cancer screening, ScreenPoint Medical has announced that its Transpara® breast imaging AI solution has been selected for the prestigious PRISM (Pragmatic Randomized Trial of Artificial Intelligence for Screening Mammography) Trial. This initiative, backed by a generous $16 million grant from the Patient-Centered Outcomes Research Institute (PCORI), marks a pivotal moment as the first large-scale trial in the United States dedicated to assessing the effectiveness of AI technology in breast cancer detection.

Led by renowned institutions UCLA and UC Davis, the PRISM Trial aims to explore whether AI can enhance the ability of radiologists to identify breast cancer at earlier stages. The goal is to improve the accuracy of mammography results while also striving to minimize unnecessary callbacks for patients, providing a more efficient experience overall. As part of the trial, focus groups and surveys will be conducted to gather insights into the patient experience and the perception of AI among both clinicians and patients.

This comprehensive study anticipates analyzing hundreds of thousands of mammograms from leading academic medical centers, including UCLA, UC Davis, UC San Diego, Boston Medical Center, the University of Miami, the University of Washington/Fred Hutchinson Cancer Center, and the University of Wisconsin–Madison. The Transpara Detection software from ScreenPoint Medical will play a crucial role in this ambitious study, demonstrating how its clinical workflow integration, facilitated by Aidoc's aiOS platform, can enhance screening processes.

Pieter Kroese, CEO of ScreenPoint Medical, expressed his excitement, stating, "This landmark trial attests to three pillars: the pioneering vision of the researchers involved, PCORI's forward-thinking perspective on technology, and the transformative potential of AI to help radiologists shape a healthier future." He emphasized the company's honor in being selected for the PRISM Trial, showing their commitment to supporting academic medical centers and breast imaging facilities in advancing earlier breast cancer detection methods, ultimately leading to more patient-centric and personalized systems of care.

ScreenPoint Medical's Transpara Breast AI has built a strong reputation based on its proven success in breast imaging AI research. Trusted by radiologists and patients alike, Transpara has analyzed over 10 million mammograms across varied imaging service lines, academic institutions, and screening programs worldwide. It stands out for its ability to enhance diagnostic accuracy, boost consistency, and maximize operational efficiency while keeping physicians at the core of every clinical decision.

As a company, ScreenPoint Medical is dedicated to revolutionizing breast health through innovative AI-powered technologies that are designed to refine every phase of the breast imaging continuum. Their solutions focus on enhancing patient experience, promoting certainty in diagnoses, and translating opportunities into meaningful health outcomes. With an eye on driving innovation and tailoring solutions for those leading the charge in breast health, ScreenPoint Medical's Transpara Breast AI is setting a new benchmark in the fight against breast cancer.

For more information about ScreenPoint Medical and their groundbreaking work in breast imaging, visit ScreenPoint Medical.